Tevogen Highlights Significant Liability Reduction and Continued Insider Control
Key Highlights
- ➤Liabilities fell to $14.8 million by September 30, 2026, from $99.9 million in 2023
- ➤Tevogen eliminated an additional $7.6 million loan obligation after September 30, 2026
- ➤Nine-month operating loss declined 17% year over year to $18.0 million
- ➤Insider ownership increased to 92% as of November 16, 2026
Expert Statements
Ryan Saadi, Founder and CEO of Tevogen
“Fiscal responsibility guides how we manage our obligations and make financing decisions.”
Ryan Saadi, Founder and CEO of Tevogen
“Retaining majority control keeps decisions about our direction and growth in the hands of our team.”
Ryan Saadi, Founder and CEO of Tevogen
“This is central to our strategy as we pursue long-term shareholder value and our ambition to redefine the future of medicine.”
* Loss from operations declined 17% year over year for the nine months ended September 30, 2026.
WARREN, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), a healthcare company focused on combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today highlighted a significant reduction in liabilities, from $99.9 million for year ended 2023 as reported on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) on May 28, 2024, to $14.8 million for the period ended September 30, 2026 as reported on Form 10-Q filed November 16, 2026. Subsequent to September 30, 2026, the Company further eliminated $7.6 million in liabilities related to a loan obligation.
Get started
Create a free account to read the full story.
